Search

everythinglearnresearchcommunity

for

Search:↓

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Merkel cell carcinoma is most likely to recur within two years of diagnosis, and factors like immune suppression, being over 75, and male sex increase this risk.

GI197111X is best dissolved in Capmul MCM for trials.

Inhibiting ornithine decarboxylase may help prevent certain skin cancers.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Targeting Keratin 17 may help overcome cancer therapy resistance.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Baricitinib helps with early hair regrowth in people with alopecia areata.

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

The treatment combination is effective and generally safe for lung cancer.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.